###begin article-title 0
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 136 144 136 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 20 23 <span type="species:ncbi:10376">EBV</span>
Epstein-Barr virus (EBV) infects resting B-lymphocytes and transforms them into immortal proliferating lymphoblastoid cell lines (LCLs) in vitro. The transformed immunoblasts may grow up as immunoblastic lymphomas in immuno-suppressed hosts.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 70 88 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 257 262 <span type="species:ncbi:4932">yeast</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 565 570 <span type="species:ncbi:9606">human</span>
###xml 1083 1086 <span type="species:ncbi:10376">EBV</span>
###xml 1159 1162 <span type="species:ncbi:10376">EBV</span>
In order to identify cellular protein targets that may be involved in Epstein-Barr virus mediated B-cell transformation, human LCL cDNA library was screened with one of the transformation associated nuclear antigens, EBNA-3 (also called EBNA-3A), using the yeast two-hybrid system. A clone encoding a fragment of a novel human protein was isolated (clone 538). The interaction was confirmed using in vitro binding assays. A full-length cDNA clone (F538) was isolated. Sequence alignment with known proteins and 3D structure predictions suggest that F538 is a novel human uridine kinase/uracil phosphoribosyltransferase. The GFP-F538 fluorescent fusion protein showed a preferentially cytoplasmic distribution but translocated to the nucleus upon co-expression of EBNA-3. A naturally occurring splice variant of F538, that lacks the C-terminal uracil phosphoribosyltransferase part but maintain uridine kinase domain, did not translocate to the nucleus in the presence of EBNA3. Antibody that was raised against the bacterially produced GST-538 protein showed cytoplasmic staining in EBV negative Burkitt lymphomas but gave a predominantly nuclear staining in EBV positive LCL-s and stable transfected cells expressing EBNA-3.
###end p 4
###begin title 5
Conclusion
###end title 5
###begin p 6
We suggest that EBNA-3 by direct protein-potein interaction induces the nuclear accumulation of a novel enzyme, that is part of the ribonucleotide salvage pathway. Increased intranuclear levels of UK/UPRT may contribute to the metabolic build-up that is needed for blast transformation and rapid proliferation.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 58 64 <span type="species:ncbi:9606">humans</span>
###xml 96 99 <span type="species:ncbi:10376">EBV</span>
###xml 192 197 <span type="species:ncbi:9606">human</span>
EBV is a gamma-herpes virus that is present in nearly all humans in form of lifelong infection. EBV infection in adolescence causes infectious mononucleosis. The virus associates with several human malignancies, particularly, with Burkitt lymphoma (BL), nasopharyngeal carcinoma (NPC) and post transplant lymphoproliferative disease [1].
###end p 8
###begin p 9
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 655 656 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 9 12 <span type="species:ncbi:10376">EBV</span>
In vitro EBV transforms B-cells into lymphoblastoid cell lines (LCLs) that express 9 virally encoded proteins - the nuclear proteins EBNA 1-6 and the membrane proteins LMP1, 2A and 2B. Six of them - EBNA-1, -2, -3, -5 and -6 and LMP-1 are required for immortalisation of B-cells [1]. EBNA-3 (also called EBNA-3A) is a member of the EBNA-3-protein family, designated as EBNA-3, 4 and 6, or in the alternative nomenclature, EBNA-3A, B and C. These three proteins bear a major responsibility for the induction of the immune rejection response that makes mononucleosis a self-limiting disease. All three proteins can bind to the DNA binding protein RBP-Jk [2-8].
###end p 9
###begin p 10
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 292 294 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 376 378 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 520 522 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 162 167 <span type="species:ncbi:4932">yeast</span>
###xml 418 435 <span type="species:ncbi:10407">Hepatitis B virus</span>
###xml 489 492 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
The role of the EBNA-3 family in the viral strategy is not well understood [9,10]. We have previously identified two cellular proteins that can bind to EBNA-3 in yeast two-hybrid system. The epsilon-subunit of the TCP1 chaperonin complex may assist the initial folding of the nascent EBNA-3 [11]. The Xap-2 protein is a minor subunit of the aryl hydrocarbon receptor complex [12]. It is also a cellular target for the Hepatitis B virus encoded X antigen. HBX is believed to be involved in HBV associated carcinogenesis [13].
###end p 10
###begin p 11
###xml 255 272 255 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Toxoplasma gondii</italic>
###xml 274 284 274 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 289 311 289 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cryptosporidium parvum</italic>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 255 272 <span type="species:ncbi:5811">Toxoplasma gondii</span>
###xml 274 284 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
###xml 289 311 <span type="species:ncbi:5807">Cryptosporidium parvum</span>
In this paper we have identified yet another human protein, designated F538, through its binding to EBNA-3. We have found that it is homologous to human and mouse uridine kinases, human uridine-cytidine kinase, and to uracil phosphoribosyltransferases of Toxoplasma gondii, C. elegans and Cryptosporidium parvum .
###end p 11
###begin title 12
Results
###end title 12
###begin p 13
###xml 345 354 345 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">clone 538</italic>
###xml 266 271 <span type="species:ncbi:9606">human</span>
###xml 512 517 <span type="species:ncbi:4932">yeast</span>
###xml 521 528 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
RBP-Jk is one of the known interacting partners of EBNA-3. It binds to the N-terminal part of EBNA-3. In order to find additional targets of this large viral protein we used an N-terminus truncated EBNA-3 cDNA clone (encoding amino acids 127-945) for screening of a human lymphoblast cDNA library. We identified an interactive clone (designated clone 538) that could grow on His, Leu and Trp deficient medium and expressed beta-galactosidase from an interaction dependent reporter locus. Plasmid rescue from the yeast to E. coli produced a clone with a ~800 bp long insert at its XhoI site.
###end p 13
###begin p 14
###xml 380 381 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 78 83 <span type="species:ncbi:4932">yeast</span>
Retransformation of clone 538 DNA together with the EBNA-3 construct into the yeast tester strain (SFY526) confirmed the interaction. Plasmids containing EBNA-1, DeltaEBNA-4, EBNA-5, EBNA-6 and the empty pGBT9/BR vector were also retransformed together with the clone 538 DNA as negative controls. None of them showed any significant interaction in beta-galactosidase test (Table 1). The strongly interacting p53/SV40LT protein pair was used as positive control.
###end p 14
###begin p 15
###xml 73 78 <span type="species:ncbi:4932">yeast</span>
Specific activity in beta-galactosidase units of 538 co-transformants in yeast strain SFY526
###end p 15
###begin p 16
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
* - Large T-p53 activity is 72,8 (30% of standard deviation after 4 independent experiments)
###end p 16
###begin p 17
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
XhoI cleaved insert of clone 538 was used as a probe on Northern blots. The 2,4 kb transcript was detected ubiquitously in all tissues with highest level expression in skeletal muscle, heart and kidney (Figure 1). We have detected the same transcript in Burkitt lymphoma (BL) lines DG75, DG75-EBNA-3, DG75-EBNA-5 and freshly established LCL (data not shown).
###end p 17
###begin p 18
###xml 85 90 <span type="species:ncbi:9606">human</span>
Northern blot for 2.4 kb F538 mRNA (top) shows an ubiquitous expression in different human tissues. beta-actin probe is used as loading control on the same filter (bottom).
###end p 18
###begin p 19
###xml 85 90 <span type="species:ncbi:9606">human</span>
Sequencing of the insert showed that clone 538 was identical to a part of a putative human gene with GenBank accession number of NM_017859.1, encoding the hypothetical gene product FLJ20517 (accession number NP_060329). The gene is consisted of fifteen exons that are distributed on a 19580 nucleotide long region on chromosome 20 (1325898-1306319).
###end p 19
###begin p 20
###xml 48 53 <span type="species:ncbi:9606">human</span>
To obtain the full-length cDNA (F538) we used a human heart cDNA library for PCR-amplification. The full-length cDNA was sequenced and cloned into green fluorescence protein fusion vector pEGFP-C1 (GFP) and AD vectors. The cDNA clone contained 1630 bp, encoding a 538 aa long protein. The first 10 amino acids were omitted from the cloning strategy because no selective primers could be designed for this region.
###end p 20
###begin p 21
###xml 310 311 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 589 590 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
We have also identified an alternatively spliced variant of this gene (F538DeltaC) where exon 12 was spliced to the middle of exon 11. This splice created a frameshift that led to a stop-codon. The encoded protein product is truncated from residue 386 with 10 extra amino acids prior to the stop-codon (Figure 2). The alternatively spliced variant was also recovered as EST from GenBank as mRNA expressed in different normal tissues such as optic nerve (BM702108), retina (BM693202) and testis (AA382318). The exon structure of the gene and the location of PCR primers are shown on Figure 3.
###end p 21
###begin p 22
###xml 125 130 <span type="species:ncbi:4932">yeast</span>
Sequence of F538 that is identical to the hypothetical protein FLJ20517. The sequence of the cDNA fragment isolated from the yeast two hybrid screen is underlined (top) Sequence of the C terminal part of the alternatively spliced variant with the additional ten amino acids preceding the newly created stop-codon (bottom).
###end p 22
###begin p 23
Exon structure and cloning strategy for the full length F538 and the C terminal truncated splice variant
###end p 23
###begin p 24
###xml 43 52 43 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro,</italic>
###xml 69 74 <span type="species:ncbi:4932">yeast</span>
To analyse the protein-protein interaction in vitro, the insert from yeast 538 clone (the coding region corresponding to amino acids 216-473) was cloned into glutathione-S-transferase bacterial expression vector (GST-2TK). Upon induction, a 56 kD fusion protein was detected on silver or Coomassie blue stained SDS acryl amide gels.
###end p 24
###begin p 25
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 153 167 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 401 415 <span type="species:ncbi:10245">vaccinia virus</span>
This and several other control GST proteins were used to precipitate interacting proteins from lysates of CV-1 cells that were infected with recombinant vaccinia virus expressing full length EBNA-3. GST-538, but not GST or GST-EBNA-5 could precipitated EBNA-3 (Figure 4). GST-Full436 containing the Xap-2 gene was used as positive interaction control [12]. Lysates of cells, infected with recombinant vaccinia virus that expressed EBNA-2 were included as non-specific precipitation controls.
###end p 25
###begin p 26
###xml 120 134 <span type="species:ncbi:10245">vaccinia virus</span>
GST-538, but not different control fusion proteins precipitates EBNA-3 from CV-1 cell lysates infected with recombinant vaccinia virus as detected by Western blotting.
###end p 26
###begin p 27
###xml 527 528 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
To study the subcellular localization of the protein, GFP-F538 and GFP-F538DeltaC constructs were transfected into CV1 cells. Protein expression was already detectable after 4-6 hours by direct fluorescence. At this time the protein was homogeneously distributed in the cytoplasm. 24 hours after the transfection the protein started to form granular precipitates of varying size that were restricted to the cytoplasm. After 48 hours the protein formed large cytoplasmic inclusion bodies as the result of overexpression (Figure 5).
###end p 27
###begin p 28
GFP-F538 localize to the cytoplasm of transfected CV1 cells. Depending on the level of expression it shows homogeneous (5-8 hours after transfection - top row), speckled (24 hours after transfection - middle row) or massively granular distribution (48 hours after transfection - bottom row). DNA staining with Hoechst 33258 is blue.
###end p 28
###begin p 29
###xml 537 563 533 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A,6B,6C,6D,6E,6F,6G,6H,6I</xref>
###xml 214 228 <span type="species:ncbi:10245">vaccinia virus</span>
EBNA-3 is a nuclear protein. In order to test if EBNA-3 has any effect on the subcellular distribution of F538, CV-1 cells that were transfected with GFP-F538 or GFP-F538DeltaC, were superinfected with recombinant vaccinia virus expressing EBNA-3 or EBNA-5. EBNA-3 but not EBNA-5 induced nuclear translocation of GFP-F538. C-terminally truncated protein remained in cytoplasm. EBNA-3 re-distributed in the nucleus and formed nuclear precipitates together with GFP-F538. These two proteins showed a high degree of co-localization (Figure 6A,6B,6C,6D,6E,6F,6G,6H,6I).
###end p 29
###begin p 30
###xml 54 68 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 447 461 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 593 599 <span type="species:ncbi:9986">rabbit</span>
###xml 660 663 <span type="species:ncbi:10376">EBV</span>
###xml 735 738 <span type="species:ncbi:10376">EBV</span>
###xml 769 772 <span type="species:ncbi:10376">EBV</span>
Expression of EBNA-3 (B, E, H - red) from recombinant vaccinia virus in cells that were transfected with GFP-F538 (A, D, G - green) leads to the accumulation of GFP-F538 in the nucleus in parallel with the redistribution of EBNA-3 from homogeneous nucleoplasmic pattern to well circumscribed nuclear granules. In these granules EBNA-3 (H) shows high levels of co-localization (I) with GFP-F538 (G). Expression of EBNA-5 (C - red) from recombinant vaccinia virus does not change the cytoplasmic localization of GFP-F538 (C - green). Immunofluorescence staining of endogeneous F538 protein with rabbit polyclonal antibodies shows cytoplasmic distribution in the EBV negative BL cells DG75 (J) but gives predominantly nuclear staining in EBV positive BL cells Raji (K) or EBV transformed lymphoblastoid cell line 940110 (L). DG75 cells that express EBNA-5 show the same cytoplasmic distribution as the parental cells (M) whereas EBNA-3 expressing DG75 cells demonstrate nuclear accumulation of the F538 protein (N). High magnification image of the nucleus show that F538 preferentially accumulates in low DNA density areas that corresponds to the euchromatin (O) DNA staining with Hoechst 33258 is blue.
###end p 30
###begin p 31
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6J</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6K</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6L</xref>
###xml 10 16 <span type="species:ncbi:9986">rabbit</span>
###xml 188 191 <span type="species:ncbi:10376">EBV</span>
###xml 285 288 <span type="species:ncbi:10376">EBV</span>
###xml 321 324 <span type="species:ncbi:10376">EBV</span>
We raised rabbit polyclonal antibodies against the bacterially produced GST-538 protein. Immunofluorescence staining detected an almost exclusively cytoplasmic distribution of F538 in the EBV negative BL cells DG75 (Figure 6J) and BL21 but gave a predominantly nuclear staining in the EBV positive BL Raji (Figure 6K) or EBV transformed lymphoblastoid cell lines Nadja, IARC171 and 940110 (Figure 6L).
###end p 31
###begin p 32
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6N</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6M</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6O</xref>
Importantly the stable transfected clone of DG75 that constitutively expressed EBNA-3 in more than 95% of the cells showed nuclear accumulation of the F538 protein (Figure 6N) whereas F538 remained cytoplasmic in DG75 cells stably transfected with EBNA-5 (Figure 6M). Optical sections taken at high magnification using fluorescence 3D microscope showed that F538 preferentially accumulated in the low DNA density areas of the nucleus of the EBNA-3 expressing cells (Fig 6O).
###end p 32
###begin p 33
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 172 175 172 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-51</sup>
###xml 221 238 221 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Toxoplasma gondii</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 302 311 302 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. gondii</italic>
###xml 597 598 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 597 598 597 598 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>R</italic></bold>
###xml 612 613 612 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 612 613 612 613 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>U</italic></bold>
###xml 635 636 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 825 834 825 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. gondii</italic>
###xml 888 889 888 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 1084 1093 1084 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. gondii</italic>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10</xref>
###xml 221 238 <span type="species:ncbi:5811">Toxoplasma gondii</span>
###xml 302 311 <span type="species:ncbi:5811">T. gondii</span>
###xml 825 834 <span type="species:ncbi:5811">T. gondii</span>
###xml 1084 1093 <span type="species:ncbi:5811">T. gondii</span>
We have built a 3D-structural model for the C-terminal part of F538, starting from residue 309, using the SWISSMODEL program [14-16]. With very high probability E-value (1e-51) it corresponded to the crystal structure of Toxoplasma gondii uracil phosphoribosyltransferase (UPRT) [17] (Figure 7). UPRT (T. gondii) belongs to PRTase-like superfamily, phosphoribosyltransferases (PRTases) family with PRTase-like fold (SCOP classification). This second half of F538 (309-548 aa) shows high sequence similarity of three of the four conserved regions (I, II and IV) where the binding sites for ribose (R) and uracil (U) are located (Figure 8). Furthermore the predicted 3D structure shows an almost identical folding even for the region III despite the sequence difference. Structure and composition of the active centre in UPRT (T. gondii) and in F538 shows also very high similarity (Figure 9). The flexible loop that is involved in the binding to another monomeric unit is present as well. The 3D model of F538 suggests that the flexible loop is folded in a similar fashion as in UPRT (T. gondii) where it is involved in the formation of homo-dimer as well as homo-tetramer, that is the active form of the enzyme (Figure 10).
###end p 33
###begin p 34
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 106 115 <span type="species:ncbi:5811">T. gondii</span>
Predicted 3D structure of F538 (aa 309-542) as space fill model in comparison to the crystal structure of T. gondii UPRT (2.5 A resolution - Schumacher et al, 1998). The bound UMP is red.
###end p 34
###begin p 35
###xml 47 64 <span type="species:ncbi:5811">Toxoplasma gondii</span>
Protein sequence alignment of F538 and UPRT of Toxoplasma gondii. The four conserved regions are underlined. R - ribose binding residue, U - uracil binding residues.
###end p 35
###begin p 36
###xml 17 26 <span type="species:ncbi:5811">T. gondii</span>
The structure of T. gondii UPRT active center with coordinated UMP (white balls and sticks) as compared to the predicted SWISSModel structure of F538. The UPRT conserved region III that shows the highest difference between the two proteins still exhibits the same folding pattern (black line on the backbone)
###end p 36
###begin p 37
The structure of the predicted dimer derived from SWISSModel for F538. Reaction product - UMP is shown in red. N - and C-termini are indicated.
###end p 37
###begin p 38
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F12">12</xref>
###xml 319 329 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
The N-terminal part contains an ATP/GTP-binding site (P-loop) suggesting that F538 also has a uridine kinase activity. High (37-42) aligning scores to the known uridine kinases support this proposition (Figure 11). F538 most probably consists of two domains with separate enzymatic activity in a similar fashion as the C. elegans UK/UPRT enzyme (Figure 12).
###end p 38
###begin p 39
###xml 89 111 89 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cryptosporidium parvum</italic>
###xml 138 148 138 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
###xml 89 111 <span type="species:ncbi:5807">Cryptosporidium parvum</span>
###xml 138 148 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
Multiple alignments of the N terminus of F538, mouse uridine kinase (P52263), UK/UPRT of Cryptosporidium parvum (AAG53652) and UK/UPRT of C. elegans (CAA93459). P-loop (ATP/GTP-binding site) is underlined.
###end p 39
###begin p 40
###xml 47 56 47 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. gondii</italic>
###xml 104 126 104 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cryptosporidium parvum</italic>
###xml 153 163 153 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 47 56 <span type="species:ncbi:5811">T. gondii</span>
###xml 104 126 <span type="species:ncbi:5807">Cryptosporidium parvum</span>
###xml 153 163 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
Multiple alignments of the C terminus of F538, T. gondii phosphoribosyltransferase (Q26998), UK/UPRT of Cryptosporidium parvum (AAG53652) and UK/UPRT of C. elegans (CAA93459).
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo</italic>
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">salvage</italic>
In the cell nucleotides are made either by the de novo pathway, or by the salvage pathway. The nucleosides can be salvaged by nucleoside kinases or cleaved by nucleoside phosphorylases to yield free bases and ribose-1-phosphate (desoxyribose-1-phosphate). The bases can be either salvaged by phosphoribosyltransferases or catabolized further.
###end p 42
###begin p 43
Uridine kinase (UK) phosphorylates uridine to uridine mono-phosphate (UMP) using ATP as a phosphate donor:
###end p 43
###begin p 44
Uridine+ATP --> UMP+ADP
###end p 44
###begin p 45
Uracil phosphoribosyltransferase (UPRT) can salvage uracil to UMP:
###end p 45
###begin p 46
PRPP+uracil --> UMP+PPi,
###end p 46
###begin p 47
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 273 276 <span type="species:ncbi:10116">rat</span>
###xml 422 427 <span type="species:ncbi:9606">human</span>
###xml 608 613 <span type="species:ncbi:9606">human</span>
###xml 641 646 <span type="species:ncbi:9606">human</span>
###xml 687 692 <span type="species:ncbi:9606">human</span>
where PRPP is 5-phosphoribosyl-1-pyrophosphate and PPi is pyrophosphate. Uridine kinases, also called ATP uridine 5' phosphotransferases, are rate-limiting enzymes in the salvage pathway. Recently it was demonstrated that uracil salvage might take place also in mammalian (rat) cells, but the responsible enzyme was still unidentified [18]. It was also shown that the activity of uridine kinases is increased 5-13 fold in human colon tumors [19] ovarian carcinomas, hepatocellular carcinomas [20] and damaged tissues [21]. The level of expression was however very low in normal tissues [22]. At present, two human uridine kinases are known: human uridine kinase 1 (HUCK1 - AAK49122) and human uridine kinase 2 (HUCK2 - AAK14053).
###end p 47
###begin p 48
###xml 182 204 <span type="species:ncbi:5807">Cryptosporidium parvum</span>
###xml 262 279 <span type="species:ncbi:5811">Toxoplasma gondii</span>
###xml 341 351 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
The N-terminal half of F538 shows high sequence similarity to both UCK1 and UCK2. UCK1 and UCK2 share 70% of identity at the protein level. F538 shows 38% identity to the UK/UPRT of Cryptosporidium parvum (accession number AAG53652), 50% identity to the UPRT of Toxoplasma gondii (accession number Q26998) and 51% identity to the UK/UPRT of C. elegans (accession number CAA93459).
###end p 48
###begin p 49
Three of four conservative domains and binding sites are present in F538 and UK/UPRT as well as in UPRT.
###end p 49
###begin p 50
###xml 119 128 <span type="species:ncbi:5811">T. gondii</span>
On the basis of the high homology to UK and UK/UPRT and the similar 3D structure of the C-terminal part of F538 to the T. gondii UPRT, we propose that F538 is a novel uridine kinas/uracil phosphoribosyltransferase (UK/UPRT) - an enzyme with double catalytic activity. The protein coded by F538DeltaC lacks the UPRT domain but may function as uridine kinase.
###end p 50
###begin p 51
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">salvage</italic>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo</italic>
###xml 239 246 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">salvage</italic>
###xml 503 508 <span type="species:ncbi:9606">human</span>
Uridine kinases and UPRTs play an important role in the salvage pathway of RNA-synthesis. It was suggested [23] that de novo synthesized UTP is preferentially used for the production of UDP-sugars and phospholipids, while UTP, made by the salvage pathway, is used for RNA-synthesis. Uridine kinase activity is increased in the tumor cells. The increase of the nuclear UTP pool may be an important factor for maintenance of high proliferation rate. We suggest that the nuclear accumulation of this novel human UK/UPRT may be part of the viral strategy to convert a resting B cell to continuously proliferating lymphoblasts by securing a salvage pathway enzyme at the site of the RNA synthesis.
###end p 51
###begin p 52
###xml 66 71 <span type="species:ncbi:4932">yeast</span>
###xml 350 355 <span type="species:ncbi:4932">yeast</span>
We have shown that F538 interacts specifically with EBNA-3 in the yeast two-hybrid system and in GST pull down assays. The predominantly cytoplasmic GFP-F538 translocates to the nucleus when EBNA-3 is expressed. GFP-F538DeltaC is not targeted to the nucleus by EBNA-3. This together with the sequence position of the cDNA fragment recovered from the yeast two hybrid screen indicates that binding site of F538 to EBNA-3 is located between residue 368 and 473, where the conserved domains of UPRT are located.
###end p 52
###begin title 53
Conclusions
###end title 53
###begin p 54
Our data suggest that EBNA-3 may bring an enzyme that participate in the uridine salvage pathway to the euchromatic part of the nucleus. Through this, EBNA-3 may contribute to the increase of UTP nuclear pool, that in turn is needed for increased cell proliferation.
###end p 54
###begin title 55
Methods
###end title 55
###begin title 56
Plasmids
###end title 56
###begin p 57
The polylinker region of the GAL-4 DNA-binding domain containing pGBT9 vector (Clontech) was modified to make it compatible with the GST-2TK expression vector (designated as BD). For AD-F538 cloning we have used pGAD424 vector from Clontech.
###end p 57
###begin p 58
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 127 129 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Construction of the plasmids Full436/GST-2TK, NEBNA-1/BD, DeltaEBNA-4/BD, EBNA-5/BD, EBNA-5/GST-2TK, was previously described [12].
###end p 58
###begin p 59
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 51 55 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
N-terminus truncated mouse p53 in pGBT9 (pVA3) and SV40 Large T-antigen in pGAD10 (pTD1, both from Clontech) were used as positive interaction controls.
###end p 59
###begin p 60
The GFP-F538 and AD-F538 were generated by inserting the 1642 bp PCR-product into the respective vectors (primers are described below) corresponding to amino acids 11 - 548 of the NP_060329.
###end p 60
###begin title 61
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast strains and cDNA library screening
###end title 61
###begin p 62
###xml 534 536 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 4 28 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 142 147 <span type="species:ncbi:9606">Human</span>
###xml 253 258 <span type="species:ncbi:4932">yeast</span>
The Saccharomyces cerevisiae HF7c strain was used for library screening and SFY526 for confirmation of the interaction upon retransformation. Human lymphocyte MATCHMAKER cDNA library in pACT GAL-4 transcriptional activation domain vector along with the yeast strains were obtained from Clontech. Library screening was done according the Clontech protocol. Interacting clones were selected on SD plates lacking His, Leu and Trp. The fastest growing clones were further tested for beta-galactosidase activity by ONPG test as described [24]. Specific activity of the given clones was calculated as percentage of beta-galactosidase units of the positive control. The samples were incubated with ONPG at 30degreesC for 2 hours.
###end p 62
###begin title 63
Sequencing
###end title 63
###begin p 64
Sequencing was done using capillary Apply BioSystem sequence machine (Perkin-Elmer).
###end p 64
###begin title 65
Northern blotting
###end title 65
###begin p 66
###xml 90 93 <span type="species:ncbi:9685">Cat</span>
Northern blotting was carried out according to manufacturer protocol on ready m-RNA blot (Cat. #7760-1, Clontech).
###end p 66
###begin title 67
PCR
###end title 67
###begin p 68
PCR was carried using Perkin-Elmer or Idahotech thermocyclers.
###end p 68
###begin p 69
Primers to amplify the F538 sequence:
###end p 69
###begin p 70
5' primers: CGGGATCCGATCCTTCGCCCACGTCGCC (for GFP), GGAATTCGATCCTTCGCCCACGTCGCC (for pGAD424).
###end p 70
###begin p 71
3' primer: GGAATTCTCACTGGGCAGCTAACCCGT (for GFP), CGGGATCCTCACTGGGCAGCTAACCCGT (for pGAD424).
###end p 71
###begin p 72
Sequencing primers:
###end p 72
###begin p 73
5' primer: CCACCCTCAAGAAGCTGAAG
###end p 73
###begin p 74
3' primer:GGTAAGCTGGTTGGTCTGGAT.
###end p 74
###begin p 75
Primers were obtained from GIBCO BRL.
###end p 75
###begin title 76
Cells and cell culture
###end title 76
###begin p 77
###xml 300 302 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 527 529 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 84 90 <span type="species:ncbi:9913">bovine</span>
###xml 245 259 <span type="species:ncbi:10245">vaccinia virus</span>
All cell lines were cultured at 37degreesC, in Iscove's medium containing 10% fetal bovine serum. Periodic staining with Hoechst 33258 was used to monitore the absence of mycoplasma. CV1 cells were infected at high multiplicity with recombinant vaccinia virus encoding EBNA-3 or EBNA-5 as described [12]. CV1 was transfected with GFP-F538 or GFP-F538DeltaC construct using Lipofectamine Plus Reagent (Life Technology) according to the manufacturer's protocol. Infection with recombinant vaccinia viruses was done as described [25].
###end p 77
###begin title 78
GST pull down assay
###end title 78
###begin p 79
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
GST pull down assay was performed as described [12]. All cell lysates contained 0,5 % of BSA as non-specific competitor.
###end p 79
###begin title 80
Immunofluorescence staining
###end title 80
###begin p 81
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 213 219 <span type="species:ncbi:9986">rabbit</span>
Immunostaining and digital image capturing was carried out as described [26-28] using the anti-EBNA-3A monoclonal antibody T2.78-19 (kind gift of M. Rowe) and anti-EBNA-5 monoclonal antibody JF186. The polyclonal rabbit antibodies against GST-538 were produced by ASLA, Ltd, Riga, Latvia.
###end p 81
###begin title 82
Molecular modelling
###end title 82
###begin p 83
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
3D modelling was run using SWISS-MODEL, an automated comparative protein modelling server [14-16]. The software was obtained from ExPASy molecular biology server .
###end p 83
###begin title 84
Multiple alignment
###end title 84
###begin p 85
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
Multiple aligning was run using Clustalw program [29] obtained from EMBL, European Bioinformatics Institute . We used the default parameters with BLOSUM matrix (gap opening value 10, gap extension value 0,05). Similar results were obtained using another aligning program - MAXHOM [30].
###end p 85
###begin title 86
Authors' contributions
###end title 86
###begin p 87
EK carried out most of the experiments and drafted the manuscript. VK participated in the cloning of the full-length cDNA. TS participated in the 3D structure predictions. GK participated in the design of the study. LS conceived of the study, and participated in its design and coordination.
###end p 87
###begin p 88
All authors read and approved the final manuscript.
###end p 88
###begin title 89
Acknowledgements
###end title 89
###begin p 90
We thank Martin Rowe for the monoclonal anti-EBNA-3 antibody. This work was supported by Cancerfonden and a matching grant from the Concern Foundation, Los Angeles, the Cancer Research Institute, New York and also by Svenska Lakarsallskapet, Sven Gards Fonden and Svenska Sallskapet for Medicinsk Forskning.
###end p 90
###begin article-title 91
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.
###end article-title 91
###begin article-title 92
###xml 30 48 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B and 3C interact with RBPJ(kappa).
###end article-title 92
###begin article-title 93
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 20 23 <span type="species:ncbi:10376">EBV</span>
###xml 69 72 <span type="species:ncbi:10376">EBV</span>
Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells.
###end article-title 93
###begin article-title 94
###xml 84 102 <span type="species:ncbi:10376">Epstein-Barr virus</span>
EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes.
###end article-title 94
###begin article-title 95
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.
###end article-title 95
###begin article-title 96
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.
###end article-title 96
###begin article-title 97
###xml 50 68 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Regulation of interleukin-1 beta transcription by Epstein-Barr virus involves a number of latent proteins via their interaction with RBP.
###end article-title 97
###begin article-title 98
###xml 15 33 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Amino acids of Epstein-Barr virus nuclear antigen 3A are essential for repression of Jkappa-mediated transcription and their evolutionary conservation.
###end article-title 98
###begin article-title 99
###xml 34 52 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa.
###end article-title 99
###begin article-title 100
###xml 30 48 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Multiple functions within the Epstein-Barr virus EBNA-3A protein.
###end article-title 100
###begin article-title 101
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus encoded nuclear protein EBNA-3 interacts with the epsilon-subunit of the T-complex protein 1 chaperonin complex.
###end article-title 101
###begin article-title 102
###xml 89 106 <span type="species:ncbi:10407">Hepatitis B virus</span>
Epstein-barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigene.
###end article-title 102
###begin article-title 103
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation.
###end article-title 103
###begin article-title 104
Protein modeling for all.
###end article-title 104
###begin article-title 105
SWISS-MODEL and the Swiss-Pdb Viewer: an enviroment for comparative protein modeling.
###end article-title 105
###begin article-title 106
The Swiss-3Dimage collection and PDB-Browser on the World-Wide Web.
###end article-title 106
###begin article-title 107
###xml 22 39 <span type="species:ncbi:5811">Toxoplasma gondii</span>
Crystal structures of Toxoplasma gondii uracil phosphoribosyltransferase reveal the atomic basis of pyrimidine discrimination and prodrug binding.
###end article-title 107
###begin article-title 108
In vitro recycling of alpha-D-ribose 1-phosphate for the salvage of purine bases.
###end article-title 108
###begin article-title 109
Enzymes of de novo and salvage pathways for pyrimidine biosynthesis in normal colon, colon carcinoma, and xenografts.
###end article-title 109
###begin article-title 110
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 96 99 <span type="species:ncbi:10116">rat</span>
Increased uridine kinase (ATP: uridine5'-phosphotransferase; EC 2.7.1.48) activity in human and rat tumors.
###end article-title 110
###begin article-title 111
###xml 94 97 <span type="species:ncbi:10116">rat</span>
Up-regulated uridine kinase gene identified by RLCS in the ventral horn after crush injury to rat sciatic nerves.
###end article-title 111
###begin article-title 112
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
Cloning and expression of cDNA encoding uridine kinase from mouse brain.
###end article-title 112
###begin article-title 113
Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides.
###end article-title 113
###begin article-title 114
###xml 19 37 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implication for down-regulation of HLA-A11 in Burkitt lymphoma.
###end article-title 114
###begin article-title 115
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies.
###end article-title 115
###begin article-title 116
###xml 112 130 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Differential expression of nucleoskeleton- and cytoskeleton-associated proteins in Burkitt lymphoma-derived and Epstein-Barr virus-immortalized lymphoblastoid cell lines.
###end article-title 116
###begin article-title 117
###xml 25 43 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 45 48 <span type="species:ncbi:10376">EBV</span>
###xml 107 110 <span type="species:ncbi:10376">EBV</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line.
###end article-title 117
###begin article-title 118
improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
###end article-title 118
###begin article-title 119
Database of homology-derived protein structures and the structural meaning of sequence alignment.
###end article-title 119

